Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1257920

Indolent extranodal B-NHL CD20 positive MALT lymphoma in a patient with primary Sjögren’s syndrome with a good response to rituximab treatment


Laktašić Žerjavić, Nadica; Pap, Mislav; Žagar, Iva; Kovač Durmiš, Kristina; Perić, Porin
Indolent extranodal B-NHL CD20 positive MALT lymphoma in a patient with primary Sjögren’s syndrome with a good response to rituximab treatment // Reumatizam, 68 (2022), 2; 86-95 doi:10.33004/reumatizam-68-2-3 (recenziran, članak, stručni)


CROSBI ID: 1257920 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Indolent extranodal B-NHL CD20 positive MALT lymphoma in a patient with primary Sjögren’s syndrome with a good response to rituximab treatment

Autori
Laktašić Žerjavić, Nadica ; Pap, Mislav ; Žagar, Iva ; Kovač Durmiš, Kristina ; Perić, Porin

Izvornik
Reumatizam (0374-1338) 68 (2022), 2; 86-95

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni

Ključne riječi
Sjögren’s Syndrome, Lymphoproliferative Disorders, B-Cell Marginal Zone Lymphoma, Rituximab

Sažetak
Sjögren’s syndrome (SS) is a chronic autoimmune disease in which chronic lymphocytic infiltration leads to progressive destruction of the exocrine glands and consequently causes the dry syndrome. The most commonly affected are the lacrimal and salivary glands. Less often, SS presents with the symptoms of exocrine glands of other localisation, arthritis, myositis, vasculitis involving the skin and the nervous system, interstitial lung disease, and kidney disease. The most serious complication is the development of lymphoproliferative disease, primarily non- Hodgkin’s lymphoma (NHL). We present the case of a patient who developed indolent extranodal B-NHL CD20-positive MALT-type lymphoma after 23 years of primary SS duration, with a good response to rituximab treatment. Sjögrenov sindrom (SS) kronična je autoimuna bolest u kojoj limfocitna infiltracija dovodi do progresivnog oštećenja egzokrinih žlijezda i sljedstvenoga suhog sindroma. Najčešće zahvaća suzne i slinovne žlijezde, a manje često se javljaju simptomi egzokrinih žlijezda druge lokalizacije, artritis, miozitis, vaskulitis sa zahvaćanjem kože i živčanog sustava, intersticijska bolest pluća i bubrežna bolest. Najteža komplikacija je razvoj limfoproliferativne bolesti, u prvom redu ne-Hodgkinovog limfoma (NHL- a). U radu prikazujemo bolesnicu koja je nakon 23 godine trajanja primarnog SS-a razvila indolentni ekstranodalni B-NHL CD20 pozitivni limfom tipa MALT uz dobar odgovor na liječenje rituksimabom.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

Napomena
U radu je tekst u cijelosti napisan na engleskom a
potom i na hrvatskom jeziku.



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb

Poveznice na cjeloviti tekst rada:

Pristup cjelovitom tekstu rada doi reumatizam.hlz.hr

Citiraj ovu publikaciju:

Laktašić Žerjavić, Nadica; Pap, Mislav; Žagar, Iva; Kovač Durmiš, Kristina; Perić, Porin
Indolent extranodal B-NHL CD20 positive MALT lymphoma in a patient with primary Sjögren’s syndrome with a good response to rituximab treatment // Reumatizam, 68 (2022), 2; 86-95 doi:10.33004/reumatizam-68-2-3 (recenziran, članak, stručni)
Laktašić Žerjavić, N., Pap, M., Žagar, I., Kovač Durmiš, K. & Perić, P. (2022) Indolent extranodal B-NHL CD20 positive MALT lymphoma in a patient with primary Sjögren’s syndrome with a good response to rituximab treatment. Reumatizam, 68 (2), 86-95 doi:10.33004/reumatizam-68-2-3.
@article{article, author = {Lakta\v{s}i\'{c} \v{Z}erjavi\'{c}, Nadica and Pap, Mislav and \v{Z}agar, Iva and Kova\v{c} Durmi\v{s}, Kristina and Peri\'{c}, Porin}, year = {2022}, pages = {86-95}, DOI = {10.33004/reumatizam-68-2-3}, keywords = {Sj\"{o}gren’s Syndrome, Lymphoproliferative Disorders, B-Cell Marginal Zone Lymphoma, Rituximab}, journal = {Reumatizam}, doi = {10.33004/reumatizam-68-2-3}, volume = {68}, number = {2}, issn = {0374-1338}, title = {Indolent extranodal B-NHL CD20 positive MALT lymphoma in a patient with primary Sj\"{o}gren’s syndrome with a good response to rituximab treatment}, keyword = {Sj\"{o}gren’s Syndrome, Lymphoproliferative Disorders, B-Cell Marginal Zone Lymphoma, Rituximab} }
@article{article, author = {Lakta\v{s}i\'{c} \v{Z}erjavi\'{c}, Nadica and Pap, Mislav and \v{Z}agar, Iva and Kova\v{c} Durmi\v{s}, Kristina and Peri\'{c}, Porin}, year = {2022}, pages = {86-95}, DOI = {10.33004/reumatizam-68-2-3}, keywords = {Sj\"{o}gren’s Syndrome, Lymphoproliferative Disorders, B-Cell Marginal Zone Lymphoma, Rituximab}, journal = {Reumatizam}, doi = {10.33004/reumatizam-68-2-3}, volume = {68}, number = {2}, issn = {0374-1338}, title = {Indolent extranodal B-NHL CD20 positive MALT lymphoma in a patient with primary Sj\"{o}gren’s syndrome with a good response to rituximab treatment}, keyword = {Sj\"{o}gren’s Syndrome, Lymphoproliferative Disorders, B-Cell Marginal Zone Lymphoma, Rituximab} }

Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font